Baseline characteristics for 28 LPL patients enrolled in the study
| . | Median . | Range . |
|---|---|---|
| Age, y | 59.5 | 33-75 |
| Male/female | 18/10 | N/A |
| Previously treated, n (%) | 23 (82.1) | N/A |
| Median prior therapies, n | 2 | 0-5 |
| Bone marrow involvement, % | 30 | 5-90 |
| Adenopathy/splenomegaly, n (%) | 5 (17.9) | N/A |
| Serum IgM, mg/dL | 3510 | 622-12 000 |
| B2M, mg/L | 3.1 | 1.3-6.9 |
| Hematocrit, % | 35.0 | 24.4-42.8 |
| Platelets, 1000/μL | 232 | 72-486 |
| Leukocytes, 1000/μL | 5.45 | 2-13 |
| . | Median . | Range . |
|---|---|---|
| Age, y | 59.5 | 33-75 |
| Male/female | 18/10 | N/A |
| Previously treated, n (%) | 23 (82.1) | N/A |
| Median prior therapies, n | 2 | 0-5 |
| Bone marrow involvement, % | 30 | 5-90 |
| Adenopathy/splenomegaly, n (%) | 5 (17.9) | N/A |
| Serum IgM, mg/dL | 3510 | 622-12 000 |
| B2M, mg/L | 3.1 | 1.3-6.9 |
| Hematocrit, % | 35.0 | 24.4-42.8 |
| Platelets, 1000/μL | 232 | 72-486 |
| Leukocytes, 1000/μL | 5.45 | 2-13 |
B2M indicates beta 2 microglobulin; and N/A, not applicable.